Related to FDA Clears Gen-Probe’s PCA3 Urine Assay for Predicting Need for Repeat Prostate Biopsies

• BioMarket Trends: The Globalization of IVD Companies
  
• Feature Articles: Metabolomics Advances Reshape Dx Arena
  
• Feature Articles: Cancer Diagnostics, Pushing the Boundaries
  
• BioPerspectives: Avoiding “Incidental” Damages
  
• Corporate Profiles: Capturing CTCs for Molecular Analysis
  
• Feature Articles: Paucity of Biopharma Approvals Raises Alarm
  
• Feature Articles: Regulatory Pathways for Molecular Dx
  
• Feature Articles: FDA Seeks to Establish Branch Office in China
  
• Feature Articles: FDA Backs PAT to Help Solve Manufacturing Woes
  
• Feature Articles: Adroit Crafting of “Intended Use” Critical
  
• Regulatory Affairs: Spotlight on the FDA
  
• Point of View: Science and Technology Are Essential to Economic Recovery
  
• Feature Articles: Banked-Specimen Retrospective Studies
  
• Regulatory Affairs: Spotlight on the FDA
  
• Spotlight on the FDA: Biosimilars and Follow-On Branded Biologics
  
• Point of View: Activism, Mendacity, and Pathological Science
  
• Spotlight on the FDA: Agency Gains Regulatory Clout
  
• Spotlight on the FDA: Update on Evolving Regulatory Guidance
  
• Spotlight on the FDA: Cracking Down on Misinformation
  
• Point of View: Pharma Innovation in Critical Condition